Shares of Cipher Pharmaceuticals Inc. (TSE:CPH - Get Free Report) NASDAQ: CPHR crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$14.60 and traded as high as C$14.82. Cipher Pharmaceuticals shares last traded at C$14.74, with a volume of 6,877 shares traded.
Analysts Set New Price Targets
Several analysts recently commented on the stock. Stifel Nicolaus decreased their price target on shares of Cipher Pharmaceuticals from C$19.00 to C$17.00 in a report on Monday, November 11th. Leede Financial cut shares of Cipher Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, September 13th.
Check Out Our Latest Report on Cipher Pharmaceuticals
Cipher Pharmaceuticals Price Performance
The stock's 50-day moving average is C$14.59 and its 200-day moving average is C$14.03. The firm has a market cap of C$365.43 million, a P/E ratio of 11.42 and a beta of 1.20. The company has a quick ratio of 2.67, a current ratio of 11.18 and a debt-to-equity ratio of 0.33.
Cipher Pharmaceuticals (TSE:CPH - Get Free Report) NASDAQ: CPHR last announced its earnings results on Thursday, November 7th. The company reported C$0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of C$0.03 by C($0.02). Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. The company had revenue of C$14.15 million for the quarter, compared to the consensus estimate of C$13.37 million. As a group, equities analysts anticipate that Cipher Pharmaceuticals Inc. will post 1.2907348 EPS for the current fiscal year.
About Cipher Pharmaceuticals
(
Get Free Report)
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
Featured Articles
Before you consider Cipher Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cipher Pharmaceuticals wasn't on the list.
While Cipher Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
